Bromocriptina

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bromocriptina

Property Description
Active ingredient Bromocriptine (often as Bromocriptine mesylate)
Form Oral tablet or capsule
Pharmacological class Dopamine agonist; Ergot alkaloid derivative
General purpose Modulating prolactin and dopamine signaling
Origin Semi-synthetic

Bromocriptina is a prescription-only medicine whose identity is defined by its active ingredient, Bromocriptine. It is chemically classified as an ergot alkaloid derivative and pharmacologically categorized as a potent dopamine agonist. This designation means the substance is a semi-synthetic compound structurally related to naturally occurring ergot compounds, engineered to specifically stimulate receptors that respond to the neurotransmitter dopamine. The medication is presented as a single-ingredient product intended for oral administration, typically in the form of a tablet or capsule.

What Type of Medicine is Bromocriptina?

Bromocriptina belongs to the class of medications known as dopamine agonists, specifically acting to stimulate D2 dopamine receptors in the brain and pituitary gland. This mechanism establishes its function as a central nervous system (CNS) modulator and a dedicated prolactin inhibitor. Bromocriptine mesylate is the established salt form used in pharmaceutical preparation, which is vital for providing necessary stability and bioavailability for effective oral absorption. Bromocriptine is notably distinguished within its class by its origin, being an ergot derivative, which separates it from newer, non-ergot agonists.

Composition and General Purpose

The medication is composed exclusively of the active ingredient, Bromocriptine, combined with solid pharmaceutical excipients that form the structural basis of the tablet or capsule. The general therapeutic utility of Bromocriptine is directly derived from its dual pharmacological actions. By activating dopamine receptors, the medicine fundamentally assists in normalizing physiological functions, such as regulating the body's natural cycle when it is disrupted by excessive prolactin. Bromocriptine is authorized as an antihyperprolactinemic agent, confirming its established role in lowering elevated prolactin levels. This classification confirms the medicine's primary benefit is helping to regulate hormonal balance.

Regulatory References

  1. EMA referral on Bromocriptine
  2. EU Register - Bromocriptine

What side effects are possible with Bromocriptina?

Possible Side Effects and Safety Information

Bromocriptine's official safety profile, as classified by regulatory authorities, details adverse reactions grouped by frequency and affected organ systems. The most very common (ge 1/10) and common side effects are predominantly gastrointestinal and neurological, including nausea, headache, dizziness, vomiting, and orthostatic hypotension (low blood pressure upon standing), which is often transient.

Less common documented effects include confusion, hallucinations, and dyskinesia (involuntary movements). These effects are classified as uncommon (ge 1/1,000 to < 1/100) in the official prescribing information.

Serious Adverse Reactions and Duration-Related Risks

The label documents specific, rare, but clinically significant risks. Fibrotic reactions, such as pulmonary fibrosis (scarring of the lungs), pleural effusion, and cardiac valvulopathy (heart valve problems), are classified as very rare (< 1/10,000). These serious adverse reactions are principally associated with long-term, high-dose exposure in patients, particularly those treated for Parkinson's disease.

Another class of documented risks includes impulse control disorders (e.g., pathological gambling, hypersexuality), which are officially listed with a not known frequency. Regulatory information also notes that effects like orthostatic hypotension are more frequently observed at treatment initiation or during dose escalation, while sudden onset of sleep is a noted risk.

Safety Restrictions

Safety restrictions prohibit the use of bromocriptine in individuals with uncontrolled hypertension, toxemia of pregnancy, and severe cardiovascular disease. Specific safety considerations are also noted for postpartum women, where use has been associated with rare reports of serious events including hypertension and seizures, necessitating monitoring.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information is derived exclusively from official government-approved prescribing information for Bromocriptina (Bromocriptine) and addresses officially documented overdose events.

In the event of a suspected overdose, it is officially required to seek immediate medical attention and contact a poison control center right away. Urgent intervention is necessary due to the potency of the medicine and the potential for serious outcomes.


Documented Overdose Manifestations

Official regulatory documents list the following clinical signs and symptoms associated with documented cases of Bromocriptine overdose:

  • Gastrointestinal Effects: Nausea and Vomiting.
  • Cardiovascular Effects: Severe Hypotension (profoundly low blood pressure).
  • Central Nervous System (CNS) Effects: Hallucinations.

Official Management and Antidote Information

When managing an overdose situation, regulatory guidance outlines the expected medical approach:

  • Antidote: No specific antidote for Bromocriptine overdose is documented in the official prescribing information.
  • Management: Treatment is defined as symptomatic and supportive. Medical care focuses on addressing the clinical manifestations, such as stabilizing blood pressure if severe hypotension occurs.

The regulatory profile emphasizes that due to the potential for severe effects like Severe Hypotension, individuals must adhere strictly to the requirement to seek immediate medical help if an overdose is suspected.

Therapeutic Uses of Bromocriptina

Bromocriptine is applied across therapeutic domains to help manage a range of conditions involving episodic or fluctuating manifestations. The medicine is commonly used to help address dysfunctions associated with hyperprolactinemia—a condition where the body produces excessive prolactin. The primary indications, which include managing symptom clusters like amenorrhea, galactorrhea, infertility, and hypogonadism, along with prolactin-secreting adenomas, are all relevant when supportive symptom management is appropriate.

It is also applied in addressing the signs and symptoms of idiopathic or postencephalitic Parkinson’s disease, which involves symptoms of increased neurological or muscular activity. Additionally, a quick-release formulation may be part of symptomatic management in conditions involving systemic imbalance, specifically type 2 diabetes. This diverse application supports general well-being during symptomatic phases by assisting with maintaining functional stability.

“Provides support that helps ease the overall symptom burden.”

Quick Fact: Relevant for easing symptoms related to systemic imbalance (e.g., Amenorrhea and Galactorrhea)

Eligibility and Restrictions for Use

Bromocriptina's eligibility is strictly defined by regulatory documents based on patient population and medical history. The medicine is contraindicated in patients with uncontrolled hypertension, all hypertensive disorders of pregnancy, and women who are nursing or lactating. Absolute prohibition also applies to those with known hypersensitivity to bromocriptine or ergot alkaloids.

Eligibility Restrictions

Classification Population or Condition
Contraindicated Uncontrolled Hypertension; Nursing/Lactating Women; Severe Cardiovascular History (for non-life-threatening use); Ergot Hypersensitivity.
Conditional Use Hepatic or Renal Impairment (Safety not established; caution advised); Geriatric Patients (Caution; low initial dose).
Not Established Most Pediatric Indications (except specific prolactinomas 11 years or acromegaly 7 years); Safety in Pregnancy (discontinuation generally advised).

Women of childbearing potential who are not seeking pregnancy must use a reliable non-hormonal contraceptive. Use during pregnancy is only considered if deemed medically necessary, such as to manage large pituitary tumors.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Bromocriptina

Property Description
Medicinal product categories with documented interactions CYP3A4 Inhibitors (Strong and Moderate), Ergot Alkaloids/Ergot-Related Drugs, Dopamine Receptor Antagonists (Neuroleptics, Antiemetics), Antihypertensive Medications, and Highly Protein-Bound Therapies.
Specific interacting medicines (if explicitly listed) Azole antimycotics, HIV protease inhibitors, Erythromycin, Ergotamine, Metoclopramide, Salicylates.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic Interaction via CYP3A4 metabolism; Pharmacodynamic Antagonism; Pharmacodynamic Synergism.
Property Description
Timing-based interaction rules (if applicable) Co-administration with ergot-related drugs is not recommended within 6 hours.
Population-specific interaction notes (if applicable) Postpartum women should not use with vasoconstrictors. Hepatic impairment may increase exposure.
Interaction-related restrictions Use with alcohol may reduce tolerance and increase CNS effects.

Official interaction statements:

  • Co-administration with strong CYP3A4 inhibitors is restricted because these agents significantly reduce the clearance of Bromocriptine, leading to increased plasma concentrations.
  • The concurrent use of Ergot Alkaloids and related drugs is contraindicated due to the potential for hypersensitivity and vasoconstrictive effects, with separation often required.
  • Dopamine Receptor Antagonists are documented to diminish the therapeutic effectiveness of Bromocriptine through pharmacodynamic conflict.
  • Caution is noted when co-administering with antihypertensive medications due to a documented risk of additive hypotensive effects.
  • Bromocriptine's high serum protein binding may lead to an increase in the unbound fraction of other highly protein-bound therapies.

Connection to the overall interaction profile

Regulatory documents define Bromocriptine's interaction structure primarily through its dependence on CYP3A4 for clearance and its susceptibility to pharmacodynamic antagonism at the dopamine receptor. The official profile mandates contraindicated and not recommended combinations, along with specific timing requirements and restrictions, establishing constraints solely to manage pharmacokinetic exposure and pharmacodynamic conflicts.

Mechanism of Action

How Bromocriptina Works

The mechanism of action for Bromocriptine involves stimulating specific dopamine receptors, which primarily affects the pituitary gland and the central nervous system (CNS).


Targeted D2 Receptor Activation and Prolactin Suppression

Bromocriptine acts as a full agonist with high intrinsic activity at the dopamine D2 receptors, particularly those found on the lactotroph cells within the anterior pituitary gland. This activation triggers an inhibitory G i-protein cascade that suppresses adenylyl cyclase activity, leading to a reduction in the synthesis and secretion of prolactin into the bloodstream. This physiological response is the basis for the drug's capacity to modulate hormonal activity by targeting the Hypothalamic-Pituitary-Prolactin Axis.


CNS Dopamine Signal Modulation for Physiological Activity

Beyond the pituitary, the drug's agonism at D2 receptors in the central nervous system, such as those in the basal ganglia, serves to enhance dopaminergic signaling in key regulatory pathways. This mechanism helps to modulate altered neuronal signaling patterns associated with motor control. The resulting physiological effect is the modulation of motor system activity and the consequence of this mechanism is a regulated state within targeted CNS pathways.

Dosage and Administration Information

Bromocriptine is administered exclusively by the oral route as an immediate-release tablet or capsule. The usage protocol for all approved conditions is structured around a low-start, gradual titration schedule, where the initial dose is incrementally increased over periodic intervals (e.g., every few days or weekly) until the optimal therapeutic maintenance level is achieved.

Administration is consistently recommended to be taken with food for all approved uses to improve tolerability. Dosing frequency and schedule are indication-specific: for hyperprolactinemia, administration is often once daily, while Parkinson's disease typically requires divided doses twice a day. The standard starting dose generally ranges from 1.25 mg to 2.5 mg daily. Maintenance dose ranges are highly specific; for instance, daily intake for hyperprolactinemia often falls between 2.5 mg and 15 mg, while doses for acromegaly or Parkinson's disease may be escalated up to 100 mg daily.

A distinct quick-release formulation (0.8 mg), used for Type 2 Diabetes, follows specialized timing instructions: it must be taken once daily within two hours after waking in the morning. The maximum daily intake for this specific formulation is 4.8 mg. If a dose of this quick-release formulation is missed, the guidance is to skip the missed dose and resume the usual regimen the following morning; doses must not be doubled. Specific dosage guidance is also established for certain pediatric patients (ages 11–15) with hyperprolactinemia, reinforcing the necessity of usage adherence according to age-specific standards.

Recent Clinical Evidence

Research evidence / Overview of studies for Bromocriptina

Evidence for use in Hyperprolactinemia and Prolactin-Secreting Tumors

Research explored the association between medication use and shifts in prolactin levels, as well as changes in tumor size in adult patients. Studies included long-standing Randomized Controlled Trials (RCTs) and Systematic Reviews. Studies report how serum prolactin levels evolved in the observed populations, noting that findings often describe patterns of shift in measured prolactin levels. For patients with prolactin-secreting tumors, research describes that changes in the tumor size were monitored during the study period. Evidence also contributes to understanding symptom patterns by reporting on changes in reported sexual function in men and patterns of change in menstrual and ovulatory cycles in a portion of women. Long-term data on the durability of symptom control after treatment is stopped is not always fully characterized.

Evidence for use in Parkinson’s Disease

Controlled Clinical Trials evaluated the medication's evaluation as an adjunct therapy or initial treatment, detailing the daily movement and activity levels and motor complications that were measured. This research primarily studied the medication for adult patients diagnosed with Parkinson’s disease, particularly when used alongside other established treatments. Research highlights changes measured during the study period in functional motor scores. Findings were mixed across the studies, and the evidence quality varies for some older research. The methodological variability of older research may limit the availability of comparative data.

Evidence for use in Type 2 Diabetes Mellitus (Quick-Release Formulation)

This evidence is based on large-scale randomized trials conducted using the quick-release formulation, detailing the specific metabolic and cardiovascular endpoints that were assessed in diabetic adult populations. The studies monitored changes in the key metabolic marker HbA1c and specifically tracked outcomes related to cardiovascular health. The existing evidence results apply only to the quick-release formulation and cannot be assumed to apply to the standard formulation. Furthermore, long-term effects are not fully established beyond the one-year treatment window of the main trial.

Key Studies & References Bromocriptine Mesylate Capsules, USP (DailyMed/FDA Label) - Indicational and Safety Data for Hyperprolactinemia and Parkinson's Disease

Frequently Asked Questions (FAQ)

Common questions about Bromocriptina (FAQ)


Q: Is Bromocriptina the same as Parlodel?

A: Bromocriptina refers to the active ingredient, bromocriptine mesylate. Parlodel is one of the commonly known brand names under which this medication is marketed. Official regulatory sources often refer to the active ingredient by its generic name, Bromocriptine.


Q: What kind of side effects are most common with Bromocriptina?

A: According to official product information, the most common side effects are typically related to the digestive system and the nervous system. These include nausea, headache, dizziness, vomiting, and orthostatic hypotension (a drop in blood pressure when standing up). These effects are frequently reported.


Q: Is it normal to feel dizzy when starting Bromocriptina?

A: Yes, regulatory documents indicate that feelings of dizziness or orthostatic hypotension (feeling lightheaded when standing) are common when starting treatment or when the dose is being increased. These effects may diminish over time as the body adjusts to the medication, but individual experience can vary.


Q: Does Bromocriptina interact with common pain relievers like ibuprofen?

A: The official product label cautions against interactions with other highly protein-bound therapies, such as salicylates, which could affect the amount of the pain reliever in the bloodstream. Official guidance emphasizes the importance of sharing a complete list of all medications, including pain relievers, with a healthcare professional due to the potential for interactions.


Q: Does Bromocriptina interact with antidepressants?

A: Bromocriptina is known to interact with certain medications that affect the central nervous system (CNS) or those that block dopamine receptors. This may include certain antidepressants. As with all medications, regulatory documents advise patients to discuss all concurrent therapies, including antidepressants, with their prescribing physician.


Q: Is it true that Bromocriptina can help regulate the menstrual cycle?

A: Studies and official information indicate that Bromocriptina is prescribed for dysfunctions caused by high prolactin levels (hyperprolactinemia). In this context, treating the underlying prolactin issue is intended to address symptoms such as irregular or absent menstrual and ovulatory cycles.


Q: What should I do if I forget to take a dose of Bromocriptina?

A: For the quick-release formulation specifically used for Type 2 Diabetes, official guidance states that if a dose is missed, it should be skipped. The guidance is to then resume the usual regimen the following morning. Doses should not be doubled.


Q: What are the serious but less common side effects of Bromocriptina?

A: Less common, but serious, effects noted in the regulatory documents include confusion, hallucinations, and dyskinesia (involuntary movements). For patients on high doses over a long period, there is a very rare risk of fibrotic reactions, such as scarring of the lungs or heart valve issues.


Q: What are the differences in side effects between immediate-release and extended-release Bromocriptina?

A: Bromocriptina is available in an immediate-release form and a quick-release formulation (Cycloset, used for diabetes). While general side effects are similar, the quick-release diabetes formulation is specifically associated with an increased risk of somnolence (drowsiness) compared to a placebo, as noted in its official labeling.


Q: Does Bromocriptina interfere with birth control pills?

A: The official product information advises women of childbearing potential who do not wish to become pregnant to use a reliable non-hormonal contraceptive. This precaution is noted due to potential concerns regarding the effectiveness of hormonal birth control.


Q: Can men take Bromocriptina?

A: Yes, regulatory documents list uses for Bromocriptina that are relevant to men. It is indicated for treating conditions associated with high prolactin (hyperprolactinemia) in men, such as hypogonadism, and for managing prolactin-secreting tumors.


Q: Can Bromocriptina be used for conditions other than high prolactin?

A: Yes, Bromocriptina has multiple approved uses. In addition to treating conditions caused by high prolactin, it is also approved for the management of Parkinson's disease and the quick-release formulation is approved to help control blood sugar in adults with Type 2 Diabetes Mellitus.


Q: Can Bromocriptina affect fertility in women?

A: Bromocriptina is indicated for the treatment of infertility in women that is caused by excessive prolactin levels. By lowering prolactin, the medication is intended to address the hormonal imbalance that can cause infertility, thereby supporting the restoration of ovulation.


Q: Does Bromocriptina affect mood or cause depression?

A: Official safety data lists mental depression as a less common side effect. More serious psychiatric effects, including hallucinations, psychosis, and impulse control disorders (like sudden strong urges), are also noted in the product information.


Q: Why do some people use Bromocriptina for Type 2 Diabetes?

A: The quick-release formulation of Bromocriptina is specifically approved to be used alongside diet and exercise to help improve glycemic control (better management of blood sugar levels) in adults who have Type 2 Diabetes Mellitus.


Q: Does Bromocriptina have an effect on sexual function?

A: Regulatory information notes that the medication may potentially cause impulse control disorders, which can manifest as increased sexual urges or unusual sexual behaviors. Additionally, treating hyperprolactinemia with the drug is indicated for conditions like hypogonadism associated with the elevated prolactin.


Q: Is it safe to drive while taking Bromocriptina?

A: Official labeling advises caution, as Bromocriptina can cause drowsiness or, rarely, a sudden onset of sleep. Due to this risk, the official label advises patients to refrain from driving or operating heavy machinery until they have determined the effect of the medication on their alertness.


Q: How does Bromocriptina help people with acromegaly?

A: Bromocriptina is an approved treatment for acromegaly, a disorder caused by the body producing too much growth hormone. The medication is indicated to manage acromegaly by acting on the hormonal system to address the underlying imbalance of growth hormone.


Q: Can Bromocriptina affect my sleep patterns?

A: Yes, the regulatory safety profile indicates that the medication can affect sleep. Side effects include somnolence (drowsiness) and the risk of sudden onset of sleep. Additionally, trouble sleeping (insomnia) is also listed as a potential side effect.


Q: Is a headache a common initial side effect of Bromocriptina?

A: Yes, regulatory product information explicitly lists a headache as a very common side effect of Bromocriptina. This may occur particularly when treatment is first initiated.


Q: Can I take Bromocriptina with cold or flu medicine?

A: Caution is advised, as Bromocriptina can interact with certain ingredients found in cold and flu medicines, such as sympathomimetic agents. These combinations can potentially cause or worsen drowsiness or affect blood pressure. Regulatory warnings indicate the need to review cold and flu product ingredients with a healthcare provider to ensure there are no unintended interactions.


Q: Is there a generic version of Bromocriptina available?

A: Yes, Bromocriptina is the active ingredient, bromocriptine mesylate, and is available from various manufacturers as a generic product in addition to the brand-name formulations.


Q: How do I know if Bromocriptina is working for my condition?

A: Effectiveness is typically determined by measuring changes in the specific clinical markers related to the condition being treated. For example, effectiveness is tracked by monitoring prolactin levels for hyperprolactinemia or functional motor scores for Parkinson's disease, as noted in the research overview.


Q: Can young adults and teenagers take Bromocriptina?

A: According to the official prescribing information, safety and effectiveness have been established for treating specific pituitary tumors in patients aged 16 to adult. Use for prolactin-related conditions is also supported by limited data for patients 11 to 15 years old.


Q: What is the source of Bromocriptina; is it a natural compound?

A: Official regulatory classification defines Bromocriptina as an ergot alkaloid derivative. This means it is a semi-synthetic compound that is chemically related to substances naturally found in ergot fungi, but it is manufactured in a laboratory setting.


Q: Can the dosage of Bromocriptina be adjusted based on lab results?

A: Yes, regulatory guidance outlines that the dosage is achieved through a gradual titration schedule until the optimal maintenance level is reached. This process is typically guided by monitoring the patient's clinical response and relevant laboratory test results.


Q: What happens in the body when Bromocriptina is taken?

A: Bromocriptina works primarily by stimulating specific dopamine D2 receptors throughout the body. This action in the pituitary gland causes it to suppress the synthesis and release of prolactin. In the central nervous system, it helps to enhance dopaminergic signaling in the pathways that regulate movement and motor control.

How should Bromocriptina be stored and disposed of?

How to Store and Dispose of Bromocriptina?

Strict adherence to official storage requirements is essential to maintain the quality and stability of Bromocriptina. This medicine must be stored at room temperature, typically between 20 C and 25 C (68 F and 77 F).

Protection from environmental factors is critical: the product should be kept in a closed, light-resistant container to shield it from direct light and moisture, as the drug substance is sensitive to light. It is also required that the medicine be kept from freezing and remain out of the reach of children.

Regarding disposal, patients should not keep outdated or unneeded medicine. Unused or expired Bromocriptina must be disposed of according to local, regional, and national regulations. To protect the environment, the medicine should not be allowed to enter sewers, surface water, or ground water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bromocriptina found in:

A-Z Index: